Logo image of MESO

MESOBLAST LTD- SPON ADR (MESO) Stock Fundamental Analysis

NASDAQ:MESO - Nasdaq - US5907174016 - ADR

18.04  +0.74 (+4.28%)

Fundamental Rating

2

Overall MESO gets a fundamental rating of 2 out of 10. We evaluated MESO against 572 industry peers in the Biotechnology industry. MESO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MESO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MESO has reported negative net income.
MESO had a negative operating cash flow in the past year.
MESO had negative earnings in each of the past 5 years.
In the past 5 years MESO always reported negative operating cash flow.
MESO Yearly Net Income VS EBIT VS OCF VS FCFMESO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of MESO (-13.14%) is better than 85.84% of its industry peers.
The Return On Equity of MESO (-18.31%) is better than 86.90% of its industry peers.
Industry RankSector Rank
ROA -13.14%
ROE -18.31%
ROIC N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
MESO Yearly ROA, ROE, ROICMESO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

MESO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MESO Yearly Profit, Operating, Gross MarginsMESO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
MESO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MESO has been increased compared to 5 years ago.
The debt/assets ratio for MESO is higher compared to a year ago.
MESO Yearly Shares OutstandingMESO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MESO Yearly Total Debt VS Total AssetsMESO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 4.64 indicates that MESO is not in any danger for bankruptcy at the moment.
MESO has a better Altman-Z score (4.64) than 80.53% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that MESO is not too dependend on debt financing.
MESO has a Debt to Equity ratio of 0.21. This is in the lower half of the industry: MESO underperforms 70.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 4.64
ROIC/WACCN/A
WACC10.72%
MESO Yearly LT Debt VS Equity VS FCFMESO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 1.18 indicates that MESO should not have too much problems paying its short term obligations.
MESO has a worse Current ratio (1.18) than 85.31% of its industry peers.
A Quick Ratio of 1.18 indicates that MESO should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.18, MESO is not doing good in the industry: 83.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 1.18
MESO Yearly Current Assets VS Current LiabilitesMESO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

MESO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.15%, which is quite good.
Looking at the last year, MESO shows a very negative growth in Revenue. The Revenue has decreased by -21.32% in the last year.
MESO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.80% yearly.
EPS 1Y (TTM)15.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.08%
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%17.53%

3.2 Future

MESO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.02% yearly.
The Revenue is expected to grow by 150.90% on average over the next years. This is a very strong growth
EPS Next Y-2.17%
EPS Next 2Y6.67%
EPS Next 3Y33.02%
EPS Next 5YN/A
Revenue Next Year51.56%
Revenue Next 2Y182.29%
Revenue Next 3Y250.52%
Revenue Next 5Y150.9%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MESO Yearly Revenue VS EstimatesMESO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
MESO Yearly EPS VS EstimatesMESO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MESO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MESO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MESO Price Earnings VS Forward Price EarningsMESO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MESO Per share dataMESO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as MESO's earnings are expected to grow with 33.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3Y33.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MESO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (1/21/2025, 8:13:46 PM)

18.04

+0.74 (+4.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2024-11-20/amc
Earnings (Next)N/A N/A
Inst Owners11.18%
Inst Owner Change0.16%
Ins Owners18.2%
Ins Owner ChangeN/A
Market Cap2.07B
Analysts77.5
Price Target14.47 (-19.79%)
Short Float %2.14%
Short Ratio4.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.75%
PT rev (3m)97.27%
EPS NQ rev (1m)0.7%
EPS NQ rev (3m)0.65%
EPS NY rev (1m)0.7%
EPS NY rev (3m)6.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 351.29
P/FCF N/A
P/OCF N/A
P/B 4.32
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-3.95
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.05
BVpS4.18
TBVpS-0.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.14%
ROE -18.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 4.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 1.18
Altman-Z 4.64
F-Score4
WACC10.72%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.22%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.08%
EPS Next Y-2.17%
EPS Next 2Y6.67%
EPS Next 3Y33.02%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%17.53%
Revenue Next Year51.56%
Revenue Next 2Y182.29%
Revenue Next 3Y250.52%
Revenue Next 5Y150.9%
EBIT growth 1Y-6.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.2%
EBIT Next 3Y80.34%
EBIT Next 5YN/A
FCF growth 1Y23.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.41%
OCF growth 3YN/A
OCF growth 5YN/A